Andrew Edge

Andrew is a senior M&A and equity capital markets lawyer with extensive experience in public and private mergers and acquisitions, IPOs and secondary offerings, joint ventures and private financing rounds.

He is one of only six London lawyers to be ranked in Tier 1 for mid-market M&A by Chambers UK legal directory as well as being listed as one of The Lawyer's Hot 100. As quoted in the legal directories, Andrew's clients describe him as 'a strong negotiator and problem solver' as well as being 'Incredibly pragmatic. The perfect sounding board for our business.'

Andrew is the UK Head of Corporate Life Sciences and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries.

While at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.

Afficher le CV complet Masquer le CV complet

Carrière

Since 2021	Partner, Taylor Wessing
2010 - 2021	Partner and Head of Corporate (2014 - 2020), Stephenson Harwood LLP
2002 - 2010	Partner, Ashurst LLP

1994 - 2002	Associate, Ashurst Morris Crisp
1992 - 1994	Articled Clerk, Ashurst Morris Crisp

Voir plus Moins

Formation

1994	Admitted as a lawyer, England and Wales
1987 - 1990	University of Birmingham, LLB Law

Expertise

Services et Groupes Fusions et acquisitions d’entreprises et marchés financiers internationaux

Secteurs Sciences de la vie et Santé

Experience

Market-leading work in the life sciences sector

We have won Life Sciences Team of the Year at the Legal Business Awards 2023 for advising on three simultaneous transformational transactions for AIM-listed Shield Therapeutics plc.

Press release

Voir l’équipe complète Masquer l’équipe

Apollo Therapeutics closes $226.5 million series C financing

We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.

Press release

Andrew Edge

Howard Palmer

Oli Denne

Voir l’équipe complète Masquer l’équipe

Prix et distinctions

Chambers and Partners UK 2023	Corporate/M&A (mid market) - Band 1: Andrew Edge is a foremost corporate practitioner to whom clients look for advice on their more significant transactions. He provides outstanding counsel on mid-market M&A and joint ventures. "Andrew Edge is a very talented lawyer; a really good operator generally." "He's got a very good practice, particularly in life sciences and tech."
Legal 500 UK 2022	M&A - lower mid-market deals, £50m-£500m (Next generation partner)